

# OPENING A NEW DOOR

to Personalized Treatment for Women with Ovarian Cancer

## Why BRCA Mutations Matter in the Battle Against Ovarian Cancer

Harmful mutations in the BRCA1 and BRCA2 genes increase a woman's risk of developing ovarian cancer.<sup>1</sup>

For women diagnosed with ovarian cancer, knowing their BRCA status – whether or not they have deleterious BRCA1 or BRCA2 mutations – **at the time of diagnosis** is important for personalizing cancer treatment therapy. The majority of women with advanced ovarian cancer **will have a reoccurrence of their cancer**, so understanding the full range of treatment options is important.<sup>2</sup>



**75%** of all women with ovarian cancer don't know their BRCA status<sup>3</sup>



About **15%** of women with ovarian cancer are **BRCA-positive** (have mutations in the BRCA1 or BRCA2 genes)<sup>4</sup>



**44%** of women with BRCA-positive ovarian cancer have no family history of cancer<sup>4</sup>

## Knowing BRCA Status is the Key to Unlocking a New Treatment Option

BRACAnalysis CDx is a **highly accurate** companion diagnostic test that identifies harmful or potentially harmful mutations in the BRCA1 and BRCA2 genes using DNA from a blood sample in order to determine a woman's BRCA status.



### What is a Companion Diagnostic?

A companion diagnostic is a test that helps doctors decide which patients could be helped by a drug and which patients would not benefit. A companion diagnostic is designed to be paired with a specific drug or therapy.<sup>5</sup>

## The New Door in Personalized Ovarian Cancer Treatment

Lynparza™ (olaparib) is the first and only FDA-approved poly ADP-ribose polymerase (PARP) inhibitor for advanced ovarian cancer patients with germline BRCA1/2 mutations who have completed three or more lines of chemotherapy.

BRACAnalysis CDx is the **first and only FDA-approved** companion diagnostic that has been proven to effectively **identify BRCA-positive ovarian cancer patients who are eligible for treatment with Lynparza**.

BRACAnalysisCDx™



as a companion diagnostic to  
**LYNPARZA**

For more detailed information about Lynparza and its safety and efficacy please visit [lynparza.com](http://lynparza.com).

For full intended use and other information about BRACAnalysis CDx please visit [myriadpro.com/bracanalysis-cdx](http://myriadpro.com/bracanalysis-cdx).

## BRCA Status Is the Key to the Door for Lynparza

Learn more at [bracnow.com](http://bracnow.com).



<sup>1</sup>National Cancer Institute. BRCA1 and BRCA2: Cancer Risk and Genetic Testing. Available at <http://www.cancer.gov/cancertopics/genetics/brca-fact-sheet#r1>.

<sup>2</sup>Ovarian Cancer National Alliance. Treatment. Available at <http://www.ovariancancer.org/about/treatment/>.

<sup>3</sup>Myriad Genetics. Data on file.

<sup>4</sup>Alsop K, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654-2663.

<sup>5</sup>U.S. Food and Drug Administration. Personalized medicine and companion diagnostics go hand-in-hand. Available at <http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm407328.htm>.



MYRIAD.

Trademarks: Unauthorized use of any Myriad trademark, service mark, or logo may be a violation of federal and state trademark law. Products, service marks or logos referenced by the Myriad company fact sheet are either trademarks or registered trademarks of Myriad and/or its affiliates in the United States and other countries. Lynparza is a registered trademark of AstraZeneca.

Copyright © 2015 Myriad Genetics, all rights reserved.

BRACAnalysisCDx™